445 related articles for article (PubMed ID: 30791936)
1. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.
Cao W; Li J; Hao Q; Vadgama JV; Wu Y
Breast Cancer Res; 2019 Feb; 21(1):29. PubMed ID: 30791936
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer.
Zhao Z; Li L; Du P; Ma L; Zhang W; Zheng L; Lan B; Zhang B; Ma F; Xu B; Zhan Q; Song Y
Theranostics; 2019; 9(5):1401-1416. PubMed ID: 30867840
[No Abstract] [Full Text] [Related]
3. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
Mehlich D; Marusiak AA
Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
[TBL] [Abstract][Full Text] [Related]
4. Demethoxycurcumin inhibits energy metabolic and oncogenic signaling pathways through AMPK activation in triple-negative breast cancer cells.
Shieh JM; Chen YC; Lin YC; Lin JN; Chen WC; Chen YY; Ho CT; Way TD
J Agric Food Chem; 2013 Jul; 61(26):6366-75. PubMed ID: 23777448
[TBL] [Abstract][Full Text] [Related]
5. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.
Johnson J; Rychahou P; Sviripa VM; Weiss HL; Liu C; Watt DS; Evers BM
PLoS One; 2019; 14(3):e0209392. PubMed ID: 30875375
[TBL] [Abstract][Full Text] [Related]
6. Triple negative breast cancer: special histological types and emerging therapeutic methods.
Cao L; Niu Y
Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
[TBL] [Abstract][Full Text] [Related]
7. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
8. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator.
Lee KH; Hsu EC; Guh JH; Yang HC; Wang D; Kulp SK; Shapiro CL; Chen CS
J Biol Chem; 2011 Nov; 286(45):39247-58. PubMed ID: 21917926
[TBL] [Abstract][Full Text] [Related]
9. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
11. Xianlinglianxiafang Inhibited the growth and metastasis of triple-negative breast cancer via activating PPARγ/AMPK signaling pathway.
Yang X; Yang R; Zhang Y; Shi Y; Ma M; Li F; Xie Y; Han X; Liu S
Biomed Pharmacother; 2023 Sep; 165():115164. PubMed ID: 37478577
[TBL] [Abstract][Full Text] [Related]
12. Role of AMPK and Akt in triple negative breast cancer lung colonization.
Johnson J; Chow Z; Lee E; Weiss HL; Evers BM; Rychahou P
Neoplasia; 2021 Apr; 23(4):429-438. PubMed ID: 33839456
[TBL] [Abstract][Full Text] [Related]
13. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
14. AMPK inhibits MTDH expression via GSK3β and SIRT1 activation: potential role in triple negative breast cancer cell proliferation.
Gollavilli PN; Kanugula AK; Koyyada R; Karnewar S; Neeli PK; Kotamraju S
FEBS J; 2015 Oct; 282(20):3971-85. PubMed ID: 26236947
[TBL] [Abstract][Full Text] [Related]
15. Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L; Duan JJ; Bian XW; Yu SC
Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
[TBL] [Abstract][Full Text] [Related]
16. Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
Mir MA; Qayoom H; Mehraj U; Nisar S; Bhat B; Wani NA
Curr Cancer Drug Targets; 2020; 20(8):586-602. PubMed ID: 32418525
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions.
Ponnusamy L; Natarajan SR; Thangaraj K; Manoharan R
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188379. PubMed ID: 32439311
[TBL] [Abstract][Full Text] [Related]
18. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
20. Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer.
Tailor D; Going CC; Resendez A; Kumar V; Nambiar DK; Li Y; Dheeraj A; LaGory EL; Ghoochani A; Birk AM; Stoyanova T; Ye J; Giaccia AJ; Le QT; Singh RP; Sledge GW; Pitteri SJ; Malhotra SV
Br J Cancer; 2021 Feb; 124(3):604-615. PubMed ID: 33139797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
